Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin launches generic...

    Lupin launches generic skin cream in US

    Written by Ruby Khatun Khatun Published On 2017-06-23T11:56:09+05:30  |  Updated On 23 Jun 2017 11:56 AM IST
    Lupin launches generic skin cream in US

    New Delhi: Drug firm Lupin said it has launched generic Desoximetasone cream used for the treatment of inflammation and itching of skin, in the US market.


    The company has launched its generic Desoximetasone cream in the strengths of 0.05 per cent and 0.25 per cent, Lupin said in a BSE filing.


    It had received approval for the product earlier from the United States Food and Drug Administration (USFDA), Lupin added.


    The company's creams are generic versions of Taro's Topicort LP emollient cream 0.05 per cent and Topicort cream 0.25 per cent respectively, Lupin said.


    "Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses", Lupin said.


    Topicort LP emollient cream 0.05 per cent and Topicort cream 0.25 per cent had combined US sales of USD 38 million as per IMS MAT April 2017 data.


    The company has 151 product filings pending approval with USFDA. Cumulative filings with the US health regulator now stand at 368 with the company having received approvals for 217 products, Lupin said.

    approvalCorticosteroidsdermatosesDesoximetasone creamgenericinflammationitchinglaunchesLupinskin creamTaroTopicortTopicort LP emollient creamUSUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok